242 related articles for article (PubMed ID: 20002447)
1. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
Copland DA; Hussain K; Baalasubramanian S; Hughes TR; Morgan BP; Xu H; Dick AD; Nicholson LB
Clin Exp Immunol; 2010 Mar; 159(3):303-14. PubMed ID: 20002447
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis.
Copland DA; Calder CJ; Raveney BJ; Nicholson LB; Phillips J; Cherwinski H; Jenmalm M; Sedgwick JD; Dick AD
Am J Pathol; 2007 Aug; 171(2):580-8. PubMed ID: 17600119
[TBL] [Abstract][Full Text] [Related]
3. Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats.
Banerjee D; Dick AD
Ocul Immunol Inflamm; 2004 Jun; 12(2):115-25. PubMed ID: 15512981
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the C5-C5a receptor axis.
Woodruff TM; Nandakumar KS; Tedesco F
Mol Immunol; 2011 Aug; 48(14):1631-42. PubMed ID: 21549429
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.
Zelek WM; Morgan BP
Front Immunol; 2020; 11():612402. PubMed ID: 33424866
[TBL] [Abstract][Full Text] [Related]
6. The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis.
Usui Y; Akiba H; Takeuchi M; Kezuka T; Takeuchi A; Hattori T; Okunuki Y; Yamazaki T; Yagita H; Usui M; Okumura K
Eur J Immunol; 2006 Nov; 36(11):3071-81. PubMed ID: 17039566
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of experimental autoimmune uveoretinitis in mice by IKKβ inhibitor IMD-0354.
Liu Y; Kitaichi N; Wu D; Hase K; Satoh M; Iwata D; Namba K; Kanda A; Noda K; Itai A; Iwabuchi K; Ishida S
Biochem Biophys Res Commun; 2020 May; 525(3):589-594. PubMed ID: 32115150
[TBL] [Abstract][Full Text] [Related]
8. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis.
Robertson M; Liversidge J; Forrester JV; Dick AD
Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):3034-41. PubMed ID: 12824249
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid phenethyl ester lessens disease symptoms in an experimental autoimmune uveoretinitis mouse model.
Choi JH; Roh KH; Oh H; Park SJ; Ha SM; Kang MS; Lee JH; Jung SY; Song H; Yang JW; Park S
Exp Eye Res; 2015 May; 134():53-62. PubMed ID: 25795054
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism.
Hoey S; Grabowski PS; Ralston SH; Forrester JV; Liversidge J
J Immunol; 1997 Nov; 159(10):5132-42. PubMed ID: 9366443
[TBL] [Abstract][Full Text] [Related]
12. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats.
Forrester JV; Huitinga I; Lumsden L; Dijkstra CD
Curr Eye Res; 1998 Apr; 17(4):426-37. PubMed ID: 9561835
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate.
Sakai T; Kohno H; Ishihara T; Higaki M; Saito S; Matsushima M; Mizushima Y; Kitahara K
Exp Eye Res; 2006 Apr; 82(4):657-63. PubMed ID: 16360654
[TBL] [Abstract][Full Text] [Related]
14. Experimental autoimmune uveoretinitis (EAU)-related tissue damage and angiogenesis is reduced in CCL2⁻/⁻CX₃CR1gfp/gfp mice.
Zhao J; Chen M; Xu H
Invest Ophthalmol Vis Sci; 2014 Oct; 55(11):7572-82. PubMed ID: 25342612
[TBL] [Abstract][Full Text] [Related]
15. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis.
Broderick C; Hoek RM; Forrester JV; Liversidge J; Sedgwick JD; Dick AD
Am J Pathol; 2002 Nov; 161(5):1669-77. PubMed ID: 12414514
[TBL] [Abstract][Full Text] [Related]
16. [Translational research with experimental autoimmune uveoretinitis (EAU)].
Usui M
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):137-58; discussion 159. PubMed ID: 17402560
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis.
Chen M; Muckersie E; Luo C; Forrester JV; Xu H
Eur J Immunol; 2010 Oct; 40(10):2870-81. PubMed ID: 20806290
[TBL] [Abstract][Full Text] [Related]
18. Complement 5 Inhibition Ameliorates Hepatic Ischemia/reperfusion Injury in Mice, Dominantly via the C5a-mediated Cascade.
Kusakabe J; Hata K; Tamaki I; Tajima T; Miyauchi H; Wang Y; Nigmet Y; Okamura Y; Kubota T; Tanaka H; Tsuruyama T; Uemoto S
Transplantation; 2020 Oct; 104(10):2065-2077. PubMed ID: 32384381
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
20. Effects of mycophenolate mofetil on nasal mucosal tolerance induction.
Dick AD; Kreutzer B; Laliotou B; Forrester JV
Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):835-40. PubMed ID: 9538893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
